Covid-19 vaccine / DCGI approves Corbevax, 12-18 year olds will get this vaccine

Another vaccine has been approved in the fight against the corona epidemic in the country. The Drugs Controller General of India (DCGI) has given final approval to the biological EK COVID-19 vaccine Corbevax for children in the age group of 12-18 years.

Biological E Ltd informed that Corbevax, India's first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against Kovid-19 for use in the age group of 12 to 18 years, has received emergency use from the drug regulator of India. approval has been obtained.

Government is buying 30 crore doses

The government is buying 30 crore doses of this corona vaccine developed by Biological E for children aged 12 to 18 years. Their purchase order was placed in August 2021. Biological E has produced 250 million doses of its vaccine, Corbevax. She will also prepare the remaining doses in a few weeks.

Last year, the government had made an advance payment of 1500 crores to Hyderabad-based company Biological E for the purchase of these vaccines. On 14 February itself, the Drug Controller of India (DGCI) allowed the emergency use of Corbevax vaccine for children between 12 and 18 years. Official sources had told ANI that the price of Corbevax would probably be Rs 145. It does not include tax.

RBD protein based vaccine

According to the Union Health Ministry, this vaccine is India's first RBD protein based Kovid-19 vaccine. This is the second vaccine after Bharat Biotech's Covaxin, to be administered to children below the age of 18 years.

What is the specialty of Corbevax vaccine?

Corbevax vaccine is administered intramuscularly. Two doses are given at an interval of 28 days. Corbevax is available in 0.5 ml (single dose) and 5 ml (ten doses) vials. It is preserved at 2 to 8 °C.